Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 33

1.

Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests.

Halbmayer WM, Weigel G, Quehenberger P, Tomasits J, Haushofer AC, Aspoeck G, Loacker L, Schnapka-Koepf M, Goebel G, Griesmacher A.

Clin Chem Lab Med. 2012;50(9):1601-5. doi: 10.1515/cclm-2011-0888.

PMID:
23100377
[PubMed - indexed for MEDLINE]
2.

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A.

Thromb Haemost. 2010 Jun;103(6):1116-27. doi: 10.1160/TH09-11-0758. Epub 2010 Mar 29. Review.

PMID:
20352166
[PubMed - indexed for MEDLINE]
3.

Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.

Wilcox R, Pendleton RC, Smock KJ, Rodgers GM.

Hosp Pract (1995). 2011 Aug;39(3):23-34. doi: 10.3810/hp.2011.08.576. Review.

PMID:
21881389
[PubMed - indexed for MEDLINE]
4.

Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists?

Guay DR.

Hosp Pract (1995). 2011 Feb;39(1):105-25. doi: 10.3810/hp.2011.02.381. Review.

PMID:
21441766
[PubMed - indexed for MEDLINE]
5.

Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.

Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A.

Thromb Haemost. 2012 May;107(5):838-47. doi: 10.1160/TH11-10-0718. Epub 2012 Feb 8. Review.

PMID:
22318514
[PubMed - indexed for MEDLINE]
6.

Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.

Baetz BE, Spinler SA.

Pharmacotherapy. 2008 Nov;28(11):1354-73. doi: 10.1592/phco.28.11.1354. Review.

PMID:
18956996
[PubMed - indexed for MEDLINE]
7.

[Dabigatran: a new therapeutic option for therapy and prophylaxis of thromboembolic diseases?].

Gassanov N, Caglayan E, Erdmann E, Er F.

Dtsch Med Wochenschr. 2010 Feb;135(6):256-9. doi: 10.1055/s-0030-1247864. Epub 2010 Jan 26. Review. German. No abstract available.

PMID:
20104442
[PubMed - indexed for MEDLINE]
8.

New options with dabigatran etexilate in anticoagulant therapy.

Maegdefessel L, Spin JM, Azuma J, Tsao PS.

Vasc Health Risk Manag. 2010 May 25;6:339-49. Review.

PMID:
20531953
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.

Ma TK, Yan BP, Lam YY.

Pharmacol Ther. 2011 Feb;129(2):185-94. doi: 10.1016/j.pharmthera.2010.09.005. Epub 2010 Oct 12. Review.

PMID:
20920530
[PubMed - indexed for MEDLINE]
10.

[Two new anticoagulants available in 2010--Dabigatran Etexilate and Rivaroxaban: expected progresses--raised problems].

Samama M, Conard J, Horellou MH, Le Flem L, Guinet C, Depasse F.

Ann Pharm Fr. 2010 Nov;68(6):359-69. doi: 10.1016/j.pharma.2010.08.001. Epub 2010 Oct 29. Review. French.

PMID:
21073994
[PubMed - indexed for MEDLINE]
11.

Dabigatran etexilate in venous thromboembolism.

Ferrer E.

Drugs Today (Barc). 2009 Oct;45(10):715-24. doi: 1396674/dot.2009.45.10.1425728. Review.

PMID:
20069135
[PubMed - indexed for MEDLINE]
12.

Dabigatran etexilate: A novel oral direct thrombin inhibitor.

Blommel ML, Blommel AL.

Am J Health Syst Pharm. 2011 Aug 15;68(16):1506-19. doi: 10.2146/ajhp100348. Review.

PMID:
21817082
[PubMed - indexed for MEDLINE]
13.

Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.

Siddiqui FM, Qureshi AI.

Expert Opin Pharmacother. 2010 Jun;11(8):1403-11. doi: 10.1517/14656566.2010.482931. Review.

PMID:
20446854
[PubMed - indexed for MEDLINE]
14.

Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges.

Mangiafico RA, Mangiafico M.

Curr Med Chem. 2012;19(27):4688-98. Review.

PMID:
22830344
[PubMed - indexed for MEDLINE]
15.

Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.

Burness CB, McKeage K.

Drugs. 2012 May 7;72(7):963-86. doi: 10.2165/11209080-000000000-00000. Review.

PMID:
22564134
[PubMed - indexed for MEDLINE]
17.

Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.

Stangier J, Clemens A.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:9S-16S. doi: 10.1177/1076029609343004. Epub 2009 Aug 19. Review.

PMID:
19696042
[PubMed - indexed for MEDLINE]
18.

Dabigatran in clinical practice.

Nagarakanti R, Ellis CR.

Clin Ther. 2012 Oct;34(10):2051-60. doi: 10.1016/j.clinthera.2012.09.008. Epub 2012 Sep 29. Review.

PMID:
23031622
[PubMed - indexed for MEDLINE]
19.

Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment.

Watanabe M, Siddiqui FM, Qureshi AI.

Neurocrit Care. 2012 Feb;16(1):203-9. doi: 10.1007/s12028-011-9591-y. Review.

PMID:
21748501
[PubMed - indexed for MEDLINE]
20.

Laboratory testing of anticoagulants: the present and the future.

Favaloro EJ, Lippi G, Koutts J.

Pathology. 2011 Dec;43(7):682-92. doi: 10.1097/PAT.0b013e32834bf5f4. Review.

PMID:
22081129
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk